NDA Submitted for Duchenne Muscular Dystrophy Drug
PTC Therapeutics announced the completion of their rolling submission of a New Drug Application (NDA) to the Food and Drug Administration (FDA) for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
The FDA has previously granted Translarna Orphan Drug status for DMD, cystic fibrosis (CF), Mucopolysaccharidosis I (MPS I), and aniridia.
Translarna is an investigational, first-in-class, oral protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation such as in nmDMD.
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Neurology Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Neurology Advisor?
Register now at no charge to access unlimited clinical news with personalized daily picks for you, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.